After completing her postdoctoral training, Sabine transitioned into the biotech industry in pursuit of bringing life-saving therapeutics to patients. For the past 15+ years, she has led drug development programs from preclinical stages through commercialization and has played a key role in bringing several highly efficacious therapies to market.
Most recently, Sabine was heading up the Program Management Office at Cellectis where she implemented governance and processes to support Cellectis’ portfolio of Cell and Gene Therapy products through the R&D life cycle. She served as Program Lead for the company’s portfolio of allogeneic CART products targeting hematological malignancies. Prior to Cellectis, Sabine managed development and partnership activities at Regeneron across various therapeutic areas, including the early development efforts of DUPIXENT® and full development life cycle of the CV Metabolism drug PRALUENT®. For the last 5 years of her tenure at Regeneron, Sabine oversaw the company’s Immuno-Oncology/Oncology therapeutic area, where she supported the growth of the portfolio from 4 to 15+ development assets while driving the strategic integration of preclinical with development needs.
Sabine completed her academic training in Germany, Canada and the US investigating cell signaling pathways involved in oncogenesis as well as immune-evasion mechanisms of Kaposi’s sarcoma-associated herpesvirus (KSHV). As a leader, Sabine values people and personal interactions. She thrives on driving cross-functional drug development efforts with a team-focused approach. Sabine is excited to be part of the Volastra team to support the company’s growth and development efforts towards bringing novel and effective therapeutic options to patients.